Omnicell, Inc. — Q1 2020 Form 10-Q
Reporting period: Three months ended March 31, 2020; unaudited. Omnicell provides medication-management automation and adherence solutions to healthcare systems and pharmacies and reports as one operating segment.
Financial results and liquidity
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Total revenue | $229.7 million | $202.5 million | Up 13% |
| Product revenue | $170.1 million | $145.6 million | Up 17% |
| Services and other revenue | $59.6 million | $56.9 million | Up 5% |
| Gross profit / gross margin | $109.6 million / 47.7% | $97.1 million / 47.9% | Profit up 13%; margin broadly stable |
| Operating income / margin | $12.2 million / 5.3% | $12.8 million / 6.3% | Income down 5% |
| Net income | $11.3 million | $3.3 million | EPS: $0.26 diluted vs. $0.08 |
| Cash from operations | $25.2 million | $26.5 million | Down 5% |
| Cash and cash equivalents, March 31 | $104.1 million | $127.2 million at Dec. 31, 2019 | Down $23.1 million |
| Debt, March 31 | $0 outstanding | $50.0 million at Dec. 31, 2019 | $50.0 million repaid in Q1 |
Operating cash flow less investment in property and equipment and capitalized software was approximately $11.5 million, compared with $9.8 million in Q1 2019. Investing cash outflow was $13.8 million. Working capital was $229.9 million, and the current ratio was 1.9:1. The company had a $500 million revolving facility available and reported compliance with its covenants.
Changes and notable items
- Revenue growth was led by XT Series automated dispensing systems, including upgrades, competitive conversions, and add-on equipment. Product revenue was 74% of total revenue, versus 72% a year earlier.
- Operating expenses rose 16% to $97.5 million, including $3.5 million of severance and related costs for a company-wide organizational realignment. Higher headcount and consulting costs also contributed.
- The effective tax provision fell to $18,000 from $8.1 million. Q1 2019 included $9.6 million of tax expense related to an intellectual-property transfer; Q1 2020 included a $2.8 million discrete tax benefit from equity compensation.
- Foreign-currency translation reduced other comprehensive income by $4.7 million in Q1 2020.
- Deferred revenue, net, increased to $114.6 million from $98.0 million at year-end. Non-cancelable purchase commitments totaled $91.7 million, including $90.2 million expected to be paid during the remainder of 2020.
Outlook, risks, and contingencies
- COVID-19: Management said Q1 revenue was not significantly affected, but customer purchasing and product bookings slowed from the second half of March into May. The company expected lower 2020 bookings and revenue than it had anticipated before the pandemic; it provided no quantified revised forecast. Delayed hospital purchasing and installations, customer financial pressure, supplier disruption, and added costs could affect results, margins, and liquidity.
- Manufacturing and distribution facilities remained open, with limited supply-chain disruption reported to date. Omnicell launched a Rapid Response program for XT Series systems and expanded remote service, training, and sales. Cost actions included reducing travel and employee-related expenses, vendor negotiations, and delaying hiring and capital expenditures.
- Management believed available cash, operating cash flow, and the revolving facility would meet needs for at least the next 12 months, while cautioning that pandemic effects and financing access remained uncertain.
- Key risks include healthcare customers delaying capital spending or implementations, product and supply-chain execution, competition, cybersecurity and privacy, and the company’s ability to execute its autonomous-pharmacy strategy.
- Omnicell reported pending product-liability and Illinois biometric-privacy litigation; it had not accrued for the described matters because it assessed losses as reasonably possible, not probable, and could not reasonably estimate a range. A separate insurer coverage dispute was dismissed with prejudice in May 2020 after settlement.
- The SEC notified Omnicell in February 2020 that its investigation into accounting processes and procedures was concluded and that it did not intend to recommend enforcement action.
Most important facts to verify
- How subsequent filings quantify COVID-related changes in bookings, installations, revenue, and full-year expectations.
- Whether customer collections, deferred revenue, inventory, and purchase commitments change materially as hospital spending and operations evolve.
- Whether gross margin and operating costs absorb pandemic-related expenses and the effects of the organizational realignment.
- Updates on the pending litigation and any resulting accruals or material loss estimates.
- Available borrowing capacity, covenant compliance, and management’s liquidity assessment in later periods.